Compare MDT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDT | VRTX |
|---|---|---|
| Founded | 1949 | 1989 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.3B | 115.7B |
| IPO Year | N/A | 1991 |
| Metric | MDT | VRTX |
|---|---|---|
| Price | $100.36 | $468.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 24 |
| Target Price | $108.44 | ★ $497.77 |
| AVG Volume (30 Days) | ★ 5.8M | 1.2M |
| Earning Date | 02-17-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 12.98 | N/A |
| EPS | 3.69 | ★ 14.22 |
| Revenue | ★ $34,758,000,000.00 | $11,723,300,000.00 |
| Revenue This Year | $8.61 | $11.01 |
| Revenue Next Year | $5.86 | $8.74 |
| P/E Ratio | ★ $26.38 | $31.56 |
| Revenue Growth | 5.34 | ★ 10.33 |
| 52 Week Low | $79.55 | $362.50 |
| 52 Week High | $106.33 | $519.68 |
| Indicator | MDT | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 63.29 |
| Support Level | $95.17 | $443.12 |
| Resistance Level | $96.99 | $455.99 |
| Average True Range (ATR) | 1.24 | 7.24 |
| MACD | -0.02 | -0.72 |
| Stochastic Oscillator | 94.41 | 88.97 |
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.